S. Hurst

发表

Utility of Genetically Modified Animal Models for Drug Metabolism and Drug Transporters

Caroline A. Lee, K. Youdim, A. Bessire, 2012 .

DRUG-DRUG INTERACTIONS FOR UDP-GLUCURONOSYLTRANSFERASE SUBSTRATES: A PHARMACOKINETIC EXPLANATION FOR TYPICALLY OBSERVED LOW EXPOSURE (AUCI/AUC) RATIOS

Barry C. Jones, Jeffrey R. Koup, Dennis A. Smith, 2004, Drug Metabolism and Disposition.

Anatomical and Physiological Factors Affecting Oral Drug Bioavailability in Rats, Dogs, and Humans

C. Loi, A. El‐Kattan, Susan I Hurst, 2011 .

Impact of physiological, physicochemical and biopharmaceutical factors in absorption and metabolism mechanisms on the drug oral bioavailability of rats and humans.

Ayman El-Kattan, C. Loi, A. El‐Kattan, 2007, Expert opinion on drug metabolism & toxicology.

Impact of physiological, physicochemical and biopharmaceutical factors in absorption and metabolism mechanisms on the drug oral bioavailability of rats and humans

C. Loi, A. El‐Kattan, J. Brodfuehrer, 2007 .

Comparative Nonclinical Assessments of the Proposed Biosimilar PF-05280586 and Rituximab (MabThera®)

M. Leach, A. Ryan, Niraj Tripathi, 2014, Toxicologic pathology.

Assessment of three human in vitro systems in the generation of major human excretory and circulating metabolites.

Deepak Dalvie, Angus Nedderman, R Scott Obach, 2009, Chemical research in toxicology.

Application of CYP3A4 in vitro data to predict clinical drug-drug interactions; predictions of compounds as objects of interaction.

Alex Phipps, R Scott Obach, Maurice Dickins, 2008, British journal of clinical pharmacology.

A significant drug-metabolizing role for CYP3A5?

J. Williams, J. Cook, Susan I. Hurst, 2003, Drug metabolism and disposition: the biological fate of chemicals.

A SIGNIFICANT DRUG-METABOLIZING ROLE FOR CYP 3 A 5 ?

J. Williams, J. Cook, Susan I. Hurst, 2003 .

James G. Stevenson, R. Popovian, J. Stevenson, 2017, The Annals of pharmacotherapy.

Key considerations in the preclinical development of biosimilars.

Carol F. Kirchhoff, A. Ryan, Susan Hurst, 2015, Drug discovery today.

A multiple-dose toxicity study of tanezumab in cynomolgus monkeys.

M. Butt, D. Shelton, M. Zorbas, 2011, Regulatory toxicology and pharmacology : RTP.

Quantitative prediction of renal transporter-mediated clinical drug-drug interactions.

Bo Feng, Brian Corrigan, Ayman El-Kattan, 2013, Molecular pharmaceutics.

Atorvastatin Glucuronidation Is Minimally and Nonselectively Inhibited by the Fibrates Gemfibrozil, Fenofibrate, and Fenofibric Acid

Chongwoo Yu, J. Bauman, T. Goosen, 2007, Drug Metabolism and Disposition.

From the Cover: Evaluation of the Effects of Tanezumab, a Monoclonal Antibody Against Nerve Growth Factor, on the Sympathetic Nervous System in Adult Cynomolgus Monkeys (Macaca fascicularis): A Stereologic, Histomorphologic, and Cardiofunctional Assessment

C. Okerberg, J. Steidl-Nichols, M. Butt, 2017, Toxicological sciences : an official journal of the Society of Toxicology.

Ocular Safety and Toxicokinetics of Bevacizumab-bvzr (Zirabev), a Bevacizumab Biosimilar, Administered to Cynomolgus Monkeys by Intravitreal Injection.

R. Sellers, M. Peraza, B. Buetow, 2023, Journal of ocular pharmacology and therapeutics : the official journal of the Association for Ocular Pharmacology and Therapeutics.

Comparison of Different Algorithms for Predicting Clinical Drug-Drug Interactions, Based on the Use of CYP3A4 in Vitro Data: Predictions of Compounds as Precipitants of Interaction

Alex Phipps, Kuresh Youdim, Maurice Dickins, 2009, Drug Metabolism and Disposition.

How Current Understanding of Clearance Mechanisms and Pharmacodynamics of Therapeutic Proteins Can Be Applied for Evaluation of Their Drug-Drug Interaction Potential

Steven W. Martin, M. Dowty, E. Kraynov, 2011, Drug Metabolism and Disposition.

Drug-drug interactions for UGT substrates: a pharmacokinetic explanation for typically observed low exposure (AUC i /AUC) ratios

Dennis A. Smith, J. Williams, J. Koup, 2004 .

Comparative Nonclinical Assessments of the Proposed Biosimilar PF-05280014 and Trastuzumab (Herceptin®)

M. Leach, T. Smolarek, A. Ryan, 2014, BioDrugs.

Effects of Monoclonal Antibodies against Nerve Growth Factor on Healthy Bone and Joint Tissues in Mice, Rats, and Monkeys: Histopathologic, Biomarker, and Microcomputed Tomographic Assessments

C. Bagi, Susan I Hurst, C. Carlson, 2018, Toxicologic pathology.

Nerve growth factor inhibition with tanezumab influences weight-bearing and subsequent cartilage damage in the rat medial meniscal tear model

A. Bendele, C. Bagi, D. Shelton, 2016, Annals of the rheumatic diseases.

Analysis of β-nerve growth factor and its precursor during human pregnancy by immunoaffinity-liquid chromatography tandem mass spectrometry

H. Neubert, J. Palandra, Shi-Kun Deng, 2023, Scientific reports.

Serum &bgr;-nerve growth factor concentrations in pregnant female, nonpregnant female, and male cynomolgus monkeys

H. Neubert, Susan I. Hurst, T. H. Clark, 2014, Neuroreport.

Synthesis and SAR of tolylamine 5-HT6 antagonists.

L. W. Cooke, Paul D. Johnson, L. Gold, 2009, Bioorganic & medicinal chemistry letters.

Sciatic nerve regeneration is not inhibited by anti-NGF antibody treatment in the adult rat

J. Kocsis, C. Somps, K. Lankford, 2013, Neuroscience.

UDP-GLUCURONOSYLTRANSFERASE 2B7 IS THE MAJOR ENZYME RESPONSIBLE FOR GEMCABENE GLUCURONIDATION IN HUMAN LIVER MICROSOMES

J. Bauman, M. Milad, T. Goosen, 2005, Drug Metabolism and Disposition.

Reaction phenotyping in drug discovery: moving forward with confidence?

J. Bauman, R. Obach, J. Gibbs, 2003, Current drug metabolism.

Bioanalytical assays in support of tanezumab developmental and reproductive toxicity studies: challenges and learnings.

B. Gorovits, T. Clark, Susan I. Hurst, 2019, Bioanalysis.

Developmental toxicity assessment of tanezumab, an anti-nerve growth factor monoclonal antibody, in cynomolgus monkeys (Macaca fascicularis).

C. Bowman, M. Butt, S. Oneda, 2014, Reproductive toxicology.

A multiple-dose toxicity study of tanezumab in cynomolgus monkeys.

M. Butt, D. Shelton, M. Zorbas, 2011, Regulatory toxicology and pharmacology : RTP.